Tracef

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tracef

Quick Facts

Property Description
Active Ingredient Ceftriaxone
Form Powder for solution for injection
Pharmacological Class Third-generation cephalosporin antibiotic
General Purpose To eliminate bacterial infections
Origin Semi-synthetic

What Type of Medicine is Tracef (Ceftriaxone)?

Tracef is a powerful prescription-only medicine (POM) whose single active ingredient is Ceftriaxone (supplied as the sodium salt). It is classified as an antibiotic, specifically belonging to the highly effective third-generation cephalosporin family of drugs. This semi-synthetic medicine is often utilized when broad-spectrum coverage is required. As a representative of the beta-lactam class, its chemical structure is designed for enhanced stability and efficacy against many types of bacterial pathogens compared to earlier generations.


Composition, Form, and Origin

The medicine is primarily formulated as a sterile powder for solution for injection, containing the active substance Ceftriaxone. This preparation requires the powder to be dissolved using a suitable reconstitution solvent before administration. This formulation necessitates delivery via the parenteral route (injection into a vein or muscle) because the drug is specifically positioned for situations demanding high, immediate systemic concentrations. Ceftriaxone is a foundational antibiotic with a therapeutic role in critical care globally.


Tracef’s General Purpose: A Bactericidal Agent

The general purpose of Tracef is to neutralize and eliminate bacterial infections through its strong bactericidal (bacteria-killing) action. Its mechanism involves acting as a cell wall synthesis inhibitor, preventing bacteria from successfully building and maintaining their protective outer layers. This focused, destructive action makes Tracef highly effective for combating systemic bacterial diseases.

Regulatory References

  1. NIH - Ceftriaxone Pharmacology and Therapeutic Use

What side effects are possible with Tracef?

Possible Side Effects and Safety Information

The safety profile of Tracef (Ceftriaxone) is classified by regulatory authorities based on the expected frequency of adverse reactions, which often involve the blood, gastrointestinal, and hepatobiliary systems. The official regulatory documents list potential effects ranging from common to rare.

Adverse Reaction Classifications

Classification Examples of Documented Effects
Common (up to 1 in 10) Eosinophilia, leukopenia, thrombocytopenia, elevated liver enzymes, diarrhea, rash.
Uncommon / Less than 1% Anemia, pruritus (itching), fever, nausea, vomiting, headache, dizziness.

Serious adverse reactions, though rare, are specifically highlighted in official labeling. These include anaphylactic shock (severe allergic reaction), severe hemolytic anemia (blood cell destruction), pseudomembranous colitis (severe diarrhea), and severe cutaneous adverse reactions like Stevens-Johnson Syndrome. The medicine carries a documented risk of superinfection (secondary infections) due to its broad-spectrum nature.

Population-Specific Safety Constraints

Regulatory information specifies several constraints, particularly regarding physical precipitation risks. The medicine must not be administered simultaneously with calcium-containing intravenous solutions due to the risk of precipitation in the body. Special consideration is given to neonates, where its use is restricted in cases of hyperbilirubinemia. Furthermore, official documents note that patients with severe combined renal and nervous system impairment may have an increased risk of serious neurological events, such as encephalopathy.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory documents define the overdose profile of Tracef (Ceftriaxone) by specific documented manifestations and mandated emergency actions. Overexposure may lead to high plasma concentrations, potentially resulting in the formation of urolithiasis (kidney stones) and precipitation of ceftriaxone-calcium salt in the gallbladder. Furthermore, high doses are associated with signs of Central Nervous System (CNS) toxicity, including convulsions.

Regulator-Mandated Action

Immediate medical attention must be sought for any suspected overdose or the manifestation of severe symptoms like convulsions or complications such as post-renal acute renal failure (PARF). Regulatory labeling confirms that no specific antidote is known, and therefore, management consists of symptomatic and supportive treatment. Hemodialysis and peritoneal dialysis are explicitly documented as ineffective procedures for reducing Ceftriaxone drug levels.

Population-Specific Risk

Official warnings highlight a severe risk for neonates (≤ 28 days of age): concomitant intravenous administration with calcium-containing solutions is associated with a risk of fatal ceftriaxone-calcium salt precipitation in the lungs and kidneys. Patients with severe renal impairment are also noted to be at increased risk of CNS toxicity from high doses.

Therapeutic Uses of Tracef

What Tracef Treats: Main Uses and Benefits

Tracef is utilized in domains involving heightened bacterial disease, where supportive symptom management is appropriate. This third-generation cephalosporin is commonly used across conditions presenting with heightened symptoms and is applied in clinical settings that involve acute or unstable symptom patterns.

Tracef is applied in addressing conditions marked by increased physiological stress, including bloodstream infections like sepsis, central nervous system infections such as bacterial meningitis, serious lower respiratory infections like pneumonia, complicated pyelonephritis (kidney infection), and deep-seated bone and joint infections.

It helps address symptom clusters that may become intense or disruptive, such as high, persistent fever and chills, or intense localized pain and swelling. The therapeutic benefit supports easing the overall symptom load and may assist with supporting general well-being during symptomatic phases marked by temporary physiological imbalance. It is also commonly used in situations involving short-term symptomatic assistance for surgical prophylaxis.

Quick Fact: Relief for Systemic Discomfort
Tracef assists with managing symptoms related to systemic imbalance (e.g., fever, chills) and organ-specific functional stress (e.g., severe shortness of breath) during acute bacterial episodes.

Eligibility and Restrictions for Use

The eligibility profile for Tracef (Ceftriaxone) is strictly defined by official regulatory documents, establishing specific populations who are allowed to use the medicine and those who must not.

Absolute Regulatory Contraindications

Tracef is contraindicated in patients with a known hypersensitivity to Ceftriaxone, any cephalosporin, or a history of a severe allergic reaction to penicillin or other beta-lactam antibiotics. Furthermore, use is strictly prohibited in certain neonates: premature infants up to 41 weeks postmenstrual age, hyperbilirubinemic neonates, and any infant 28 days old or younger who requires intravenous calcium-containing solutions. Simultaneous IV administration with calcium-containing products is prohibited in all patients.

Age and Condition Restrictions

Use is established for adults, adolescents, and children 15 days of age and older. Older adults with satisfactory liver and kidney function typically do not require modification. However, the label specifies restricted use for patients with co-existing severe hepatic and renal impairment, who must adhere to a maximum daily limit. Use during pregnancy is permitted only if clearly needed, and caution is advised during lactation as the substance is excreted in breast milk. The medicine must also not be administered intravenously if reconstituted with a lidocaine-containing solvent.

What should I know about interactions with other medicines?

Primary Interaction Constraints

Restriction Type Interacting Substance Regulatory Constraint
Absolute Contraindication Calcium-Containing IV Solutions Co-administration is prohibited in all patients due with the risk of precipitation formation.
Neonatal Contraindication Hyperbilirubinemic Neonates Use is prohibited due to the potential for Ceftriaxone to displace bilirubin from albumin binding sites.

Pharmacodynamic and Pharmacokinetic Interactions

Interaction Outcome Interacting Substance Regulatory Statement
Coagulation Alteration Vitamin K Antagonists (e.g., Warfarin) Increases the anticoagulant effect, officially prolonging the prothrombin time (INR) and increasing bleeding risk.
Increased Exposure Probenecid Expected to increase systemic exposure by inhibiting renal clearance.
Antagonism Risk Bacteriostatic Agents (e.g., Chloramphenicol) Officially noted risk of pharmacodynamic antagonism of the bactericidal effect.

The official regulatory documents define the interaction profile around the chemical incompatibility with intravenous calcium and the effects on blood coagulation. For patients older than 28 days, sequential administration of Tracef and calcium-containing infusions is permitted only if the IV line is thoroughly flushed between infusions, a procedural constraint defined in regulatory labels.

Mechanism of Action

Tracef is a human monoclonal antibody that selectively binds to the Receptor Activator of NF-kappaB Ligand (RANKL). This binding primarily occurs within the bone microenvironment, preventing RANKL from engaging its cognate Receptor Activator of NF-kappaB (RANK) receptor. The RANK receptor is located on the surface of pre-osteoclasts and mature osteoclasts.

By occupying RANKL, Tracef functions as a targeted inhibitor of the RANKL/RANK signaling pathway, which is essential for osteoclast differentiation, activation, and survival. Modulation of this binding process disrupts the intracellular signaling cascade necessary for osteoclast formation and function. Consequently, this action leads to a significant decrease in the number and activity of osteoclasts. The resultant reduction in osteoclast-mediated bone resorption shifts the balance of bone remodeling and modulates the net ratio of osteoblast-to-osteoclast activity.

Dosage and Administration Information

How to Use Tracef (Ceftriaxone)

Tracef is administered through the parenteral route, which means it is delivered via intravenous (IV) injection or infusion, or intramuscular (IM) injection. It is supplied as a sterile powder that requires reconstitution with a suitable diluent before use.


Standard Administration Patterns

Administration is typically given once daily (every 24 hours). For adults, the standard daily dose ranges from 1 g to 2 g, although the total daily dose should generally not exceed 4 g for severe infections. In the context of surgical prophylaxis, a single dose of 1 g or 2 g is administered prior to the procedure. Treatment duration is variable, but generally continues for a minimum of 48 to 72 hours after the patient becomes afebrile.


Specific Procedural Constraints

The formulation imposes strict limitations on preparation and delivery. For IV administration, the solution must be given slowly, over 2 to 4 minutes for injection, or over 30 minutes for infusion. When the IM route is utilized, doses over 1 g must be divided and injected into separate sites, and a diluent containing Lidocaine may be used, which is strictly forbidden for IV use. A critical administration constraint is that Tracef must not be simultaneously mixed with or administered with calcium-containing intravenous solutions (such as Ringer’s or Hartmann’s solution).


Population-Based Dosing

Pediatric dosing is based on body weight. For adults, dosage adjustment is not typically required for single-organ dysfunction (renal or hepatic) if the daily dose is 2 g or less, but the dose should be limited to 2 g daily for patients with both severe renal and hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tracef (Ceftriaxone)

This overview summarizes the existing research base for Tracef, describing the types of studies conducted, the outcomes they monitored, and the areas where research remains uncertain. This is not clinical guidance and does not contain personal health advice.


Research Evidence for Severe Respiratory and Systemic Infections (Pneumonia and Sepsis)

The evidence for research focusing on Tracef in the context of serious infections like Community-Acquired Pneumonia (CAP) relies heavily on Randomized Controlled Trials (RCTs) and large retrospective cohort studies. The compound was evaluated in large groups of hospitalized adults, including older adults and those with various underlying health conditions.

Studies monitored key public health and clinical outcomes, such as all-cause mortality (often tracked 30 to 90 days after treatment) and measures of clinical success. Studies monitored outcomes when Tracef was used and compared them to patterns observed with other antibiotic regimens in these groups.

Evidence Supporting Use in Central Nervous System and Urinary Tract Infections

The evidence structure for Tracef in the context of Bacterial Meningitis involves a specialized body of evidence, including RCTs and Pharmacokinetic/Pharmacodynamic (PK/PD) studies. PK/PD research specifically examines how much of the drug is able to cross into the Cerebrospinal Fluid (CSF). Trials examined patient groups that included infants, children, and adults, with outcomes focused on the resolution of clinical signs and symptoms and microbiological clearance from the CSF.

For complicated infections of the kidney and urinary tract (Pyelonephritis), the evidence is primarily drawn from Comparative Clinical Trials and subsequent Meta-analyses. These studies monitored both microbiological success and clinical success in hospitalized patients.

Areas of Research Uncertainty and Study Gaps

Research is ongoing and certainty remains low in certain areas. Key evidence gaps include uncertainty regarding the optimal dosing for all patient severities, as findings have been mixed across trials. Additionally, dedicated data are generally not available for studies involving certain highly vulnerable groups, such as hyperbilirubinaemic neonates, due to specific regulatory constraints.

Key Studies & References

  1. Evidence review for antibiotics for bacterial meningitis before or in the absence of identifying causative infecting organism in adults (NICE Guideline NG240 supporting evidence)
  2. A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone: a study of wound, chest, and urinary infections (DARE Summary)

Frequently Asked Questions (FAQ)

Common questions about Tracef (FAQ)


Q: How long does it typically take to start noticing the effects of Tracef?

A: Tracef is designed to begin working quickly in the body to eliminate bacteria soon after administration. However, the time it takes for a patient to experience symptomatic relief can vary based on the infection type and severity.

Q: Are there any common reasons why Tracef might stop working for someone?

A: Official information indicates that antibiotics like Tracef should only be used for infections confirmed or strongly suspected to be bacterial to reduce the risk of developing drug-resistant bacteria. The official product information also notes a potential risk of antagonism when Tracef is used with certain other medications, which could influence effectiveness.

Q: What should I do if a side effect feels severe?

A: Official guidance states that if serious reactions occur, such as a severe allergic reaction (hypersensitivity) or neurological event, the drug should be discontinued and appropriate supportive measures should be instituted.

Q: Do I need special monitoring or blood tests while on Tracef?

A: Official safety information reports potential changes to blood cell counts and liver enzyme values as possible adverse reactions. These factors are often monitored during the course of treatment to ensure patient safety.

Q: What types of mental or emotional side effects are possible with Tracef?

A: Serious neurological adverse reactions are reported in official safety information, including disturbances of consciousness such as somnolence (drowsiness), lethargy, and confusion. Less commonly, general side effects like headache and dizziness are also noted.

Q: Do I need to avoid any specific foods or drinks while taking Tracef?

A: Official regulatory documents and patient information state there are no known interactions between Tracef and general foods or drinks. The primary and critical restriction noted in regulatory documents involves the strict constraint against simultaneously co-administering the drug with intravenous calcium-containing solutions.

Q: Does Tracef interact with birth control pills?

A: Tracef belongs to a class of broad-spectrum antibiotics. Authoritative sources note that broad-spectrum antibiotics are generally not expected to reduce the effectiveness of combined hormonal contraceptives.

Q: Why do official documents list so many potential interactions?

A: Regulatory bodies require official drug documents to describe all known or potential interactions to ensure patient safety. These listings cover how the drug might affect other medications, such as increasing the effect of blood thinners, or chemical incompatibilities, like the stated risk of precipitation with calcium.

Q: Is Tracef available as a generic medication?

A: Yes, the active ingredient in Tracef is ceftriaxone, which is widely available as a generic medication from various manufacturers. The generic version is required by regulatory agencies to meet the same strict standards for quality, strength, purity, and effectiveness as the original brand product.

Q: Are there any common over-the-counter medicines that interact with Tracef?

A: The official prescribing information specifically mentions interactions with certain prescription medications, such as Vitamin K antagonists (like Warfarin). There are generally no common over-the-counter medicines explicitly listed in the drug interaction tables.

Q: Does alcohol make the side effects of Tracef worse?

A: Tracef is not known to cause a severe reaction when combined with alcohol, unlike some other antibiotics. However, official sources note that alcohol use may potentially increase certain side effects, such as dizziness, and its use is typically not recommended during the antibiotic course.

Q: Is it safe to drive while taking Tracef?

A: The regulatory information lists potential side effects like dizziness and, in rare instances, serious neurological adverse reactions. The presence of side effects such as dizziness or confusion suggests that caution regarding activities requiring full mental alertness, such as driving, may be warranted if these effects occur.

Q: How long does Tracef stay in your system after stopping treatment?

A: The elimination half-life of ceftriaxone in healthy adults is officially reported to be between 5.8 and 8.7 hours. Based on this, it typically takes about two days for the drug to be almost entirely cleared from the body after the last dose is given.

Q: Is Tracef a controlled substance?

A: No, Tracef (ceftriaxone) is classified as a prescription-only medicine but is not scheduled as a controlled substance by regulatory bodies. The drug is an antibiotic and is not associated with the risk of physical or psychological dependence.

Q: Are there any studies comparing Tracef to non-drug treatments?

A: Official research summaries primarily describe studies comparing Tracef to other antibiotic regimens in the context of bacterial infections. Research evidence does not typically include comparisons to non-drug interventions, as the drug is intended for specific bacterial disease treatment.

Q: Is there a possibility of becoming dependent on Tracef?

A: Tracef is an antibiotic used for short-term bacterial infection treatment. It belongs to a drug class that is not associated with the risk of physical or psychological dependence.

Q: Do the side effects of Tracef usually go away over time?

A: While most common side effects are temporary, the official label specifically notes that serious neurological adverse reactions were generally found to be reversible and resolved after the drug was discontinued.

Q: What's the difference between the brand name and the generic version of Tracef?

A: The generic version, ceftriaxone, contains the exact same active ingredient as the brand name. It is required by regulatory agencies to meet the same strict standards for quality, strength, purity, and effectiveness, ensuring it works the same way in the body.

Q: Has Tracef ever been recalled?

A: Official records indicate that the original brand name product was voluntarily discontinued from the market by the manufacturer. Regulatory determination confirmed that this withdrawal was not due to safety or effectiveness concerns.

Q: Are there any long-term health concerns associated with using Tracef for many years?

A: Tracef is indicated as a short-course antibiotic for acute bacterial infections. Regulatory information and safety profiles primarily focus on this short duration of treatment, as the drug is neither intended nor evaluated for long-term use over many years.

Q: Is Tracef affected by grapefruit?

A: No official interaction is noted or expected. Tracef is typically administered by injection and is not metabolized by the specific liver enzymes (CYP enzymes) commonly affected by grapefruit.

Q: Why do some people need a lower dose of Tracef?

A: Official regulatory documents specify that the maximum daily dosage may need to be limited for adult patients who have co-existing severe impairment of both their kidney (renal) and liver (hepatic) function.

Q: How do researchers measure if Tracef is working?

A: Researchers monitor several key clinical outcomes to evaluate the drug's effectiveness in studies. These outcomes include measures of clinical success (resolution of symptoms) and the clearance of bacteria from the body, in addition to tracking all-cause patient mortality.

Q: What is the typical duration of treatment with Tracef?

A: The total duration of treatment is determined by the specific infection. While the minimum treatment length is stated as 48 to 72 hours after fever resolution, many standardized protocols for specific infections range from 4 to 14 days, depending on the severity and type.

Q: Can Tracef cause stomach problems?

A: Yes, official safety information lists gastrointestinal effects, including diarrhea, nausea, and vomiting, as potential side effects. A more severe form of diarrhea called pseudomembranous colitis is also listed as a rare but serious adverse reaction.

Q: Why do people sometimes stop taking Tracef?

A: Treatment is stopped either because the course of therapy has been successfully completed and the infection resolved, or if a severe adverse reaction occurs. Official guidelines advise discontinuing the drug immediately in the event of a serious allergic or neurological reaction.

Q: Is there a chance Tracef won't work for me?

A: Clinical evidence demonstrates that while Tracef is generally effective, there can be variability in individual patient response. Research has noted areas of uncertainty regarding the optimal dosing for all patient severities, which can influence a patient's outcome.

How should Tracef be stored and disposed of?

How to Store and Dispose of Tracef (Ceftriaxone)

Tracef (ceftriaxone) storage requirements vary based on whether the product is an unopened dry powder or a reconstituted solution, with all instructions strictly defined in official regulatory labeling.


Official Storage Conditions

The dry powder for injection must be stored at controlled room temperature, specifically below 25 C (77 F), and must be protected from light by keeping it in its original container. The powder must not be frozen.

Once reconstituted, the solution has a limited stability period: 6 hours at room temperature or 24 hours under refrigeration (2 C to 8 C). The solution should be inspected for particles; any unused or discolored solution must be discarded.

Disposal and Safety

All medicine must be kept out of the sight and reach of children. Unused or expired Tracef must not be thrown away via wastewater or household waste. Disposal must be performed according to local requirements, typically through an approved medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tracef found in:

A-Z Index: